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Purpose or Objective: A majority of patients with rectal 
cancer is treated with neoadjuvant radiotherapy, with or 
without chemotherapy. If after chemoradiation (CRT) 
patients show a good clinical response, organ-preserving 
strategies are increasingly being offered. To increase the 
amount of patients with a good clinical response, it has been 
proposed to replace short-course radiotherapy (SCRT) by 
CRT. However, intensified treatment may affect patients’ 
quality of life (QoL). This study aims to compare self-
reported QoL between routinely treated rectal cancer 
patients receiving SCRT versus CRT before, during and after 
treatment. 
 
Material and Methods: This multicenter prospective cohort 
study includes rectal cancer patients of all stages referred 
for radiotherapy between February 2013 and May 2015. QoL 
was assessed by EORTC-C30 and -CR29 questionnaires at 
baseline, 3, 6 and 12 months. For each patient, a propensity 
score (PS) for receiving CRT was calculated and used for 
restriction and adjustment. Changes in QoL over time were 
analyzed by mixed models between patients receiving CRT 
and SCRT, and additionally compared to a normative age-
matched Dutch population. 
 
Results: After PS based restriction, 191 of 208 eligible 
patients were included, of which 69 underwent SCRT and 122 
CRT. Patients undergoing CRT were younger (62.2 vs. 68.0 
year), had more mesorectal fascia invasion (66.6% vs. 27.9%), 
more T4 (20.5% vs. 11.6%) and less T2 tumors (3.3% vs. 
11.6%). Questionnaire return rates were 84% at baseline and 
63-80% during follow-up. In both groups, 3 and 6 months QoL 
scores for global health, physical, emotional, social and role 
function were lower than at baseline and similar in both 
groups at all time points. At 12 months, all functional scores 
in both groups returned to baseline level, except for role 
function. No significant differences were found on symptom 
scales (constipation, diarrhea, pain, fatigue, nausea) 
between SCRT- and CRT-patients. Compared to the Dutch 
reference population, patients with rectal cancer still had 
impaired role and social function at 12 months. 
 
 
Conclusion: Over the course of neoadjuvant rectal cancer 
treatment, similar drops in QoL are observed for patients 
receiving SCRT or CRT. After 12 months, most QoL scores 
return to baseline levels. 
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Purpose or Objective: Protontherapy is a standard treatment 
for uveal melanomas. One area of current controversy is the 
use of protontherapy for uveal melanomas of temporal 
superior location owing to the presence of the lacrimal gland 
and the risk of radiation-induced dry eye syndrome (DES). 
Some teams have been contra-indicating such tumor locations 
for protontherapy and advocate brachytherapy. We 
investigated whether temporal superior (TS) melanomas 
should no longer be treated with proton therapy based on the 
rate of severe non manageable complications for DES. 
 
Material and Methods: This retrospective study includes 
consecutive patients treated from 1999 to 2014 with 
protontherapy at our center. Patients received 52 Gy in four 
fractions and four days. Conjunctival melanomas were not 
excluded. Melanoma location was determined using an 
oriented clockwise goniometer. DES grades were defined as 
Group 0 : no sign of dry eye, group 1: discomfort, group 2: 
keratitis, group 3 (severe): corneal ulcer. Percentages of the 
lacrimal gland receiving 90% of the prescribed dose, 20% to 
50% or ≤ 20% were assessed in the frontal and sagittal planes 
in Eyeplan blindly by two operators. The spss v12 statistics 
software was used. Kaplan Meier curves and Log rank tests 
were used for survival data. 
 
Results: Of 1445 patients in the study, 14.7% and 2.0% had 
DES and severe DES, respectively. Two and five year DES-free 
survival rates were 88.9% and 83.6%, respectively. There 
were 7.6% melanomas of TS location. DES and severe DES 
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correlated with TS location 13.8% vs 24.8% and 1.7% versus 
5.8% in case of non-TS and TS (p < 0.05). 21/25 of patients 
with severe DES were in TS or temporal location. No patient 
had enucleation for DES. On MVA, diameter (hazard ratio 
HR:1.103, CI95:1.042-1.169, p 0.001), tumor volume 
(HR:0.0696, CI95:0.486-0.996, p=0.048, % of ciliary body in 
the 90% isodose line (HR:1.014, CI95:1.003-1.026, p=0.015), 
gel compensator (HR:0.717, CI95:0.535-0.960, p=0.025) and 
TS location (HR:2.581, CI95:1.695-3.929, p<0.001) were 
significantly associated with the occurrence of DES. 
 
Conclusion: Although the incidence of DES and severe DES 
was increased in TS melanomas and this correlated with the 
dose to the lacrimal gland, their characteristics were less 
favorable (larger, superior involvement of ciliary body and 
limbus). Occurrence of severe DES in TS but also temporal 
locations suggests that involvement of the ciliary arteries 
may also be responsible for severe DES. The correlation of TS 
with ciliary involvement suggests that limbus cells may 
participate in the occurrence of DES. The role of palpebral 
and corneal irradiation will be further investigated. Since DES 
is manageable, TS location should not be considered a 
contraindication for protontherapy. 
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Purpose or Objective: In parapapillary melanoma patients, 
radiation-induced optic complications are frequent and visual 
acuity is often compromised. We investigated dose effect 
relationships for the optic nerve with respect to visual acuity 
after protontherapy. 
 
Material and Methods: of 5205 patients treated between 
1991 and 2014, those treated between 1994 and 2013 (using 
CT-based planning) to 52 Gy in four fractions, minimal 6 
month follow-up and documented initial and last visual 
acuity, were included. Deterioration of ≥ 0.3 logMAR between 
initial and last visual acuity was reported. 
 
Results: 865 consecutive patients were included. Median 
follow-up was 69 months, mean age 61.7 years, tumor 
abutted the papilla in 64.9% and tumor to fovea distance was 
≤ 3 mm in 74.2% of patients. Five-year relapse-free survival 
rate was 92.7%. Initially, 72.6% of patients had ≥ 20/200 
visual acuity, 47.2% had ≥ 20/200 at last follow -up. A wedge 
filter was used in 47.8% of the patients, with a positive 
impact on vision and no impact on relapse. Glaucoma, 
radiation-induced optic neuropathy, maculopathy were 
reported in 17.9%. 47.5%, and 33.6%, respectively. Patients 
irradiated to ≥ 80% of their papilla had better visual acuity 
when limiting the 50% (30 Gy) and 20% (12 Gy) isodoses to ≤ 2 
mm and 6 mm of optic nerve length, respectively. 
 
Conclusion: A personalized protontherapy plan can be used 
efficiently with good oncologic and functional results in 
parapapillary melanoma patients. 
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Purpose or Objective: To estimate the toxicity and efficacy 
of carbon ion radiotherapy for adenoid cystic carcinomas 
(ACC) invading the skull base. 
 
Material and Methods: Between April 1997 and August 2013, 
a total of 193 patients with ACC of the head-and-neck were 
treated with carbon ion radiotherapy. All of these patients 
had neither regional lymph node nor distant metastasis 
before carbon ion radiotherapy. The prescribed tumor doses 
were 57.6 or 64.0 Gy (RBE) in 16 fractions over four weeks. 
Of the 193 patients, 78 patients with ACC invading the skull 
base were analyzed. There were 37 males and 41 females. 
The median age was 52 years (range, 23-75 years). The most 
common primary site was the parenasal sinus (46%), followed 
by the nasopharynx (13%), the nasal cavity (10%) and the hard 
palate (10%). The extent of surgery was biopsy alone in 52 
patients (67%), partial resection in 5 patients (6%). Twenty of 
78 patients (27%) had recurrence tumors after surgery. 
Median follow-up time was 52 months (range, 10-177.7 
months). Patients were divided into two groups according to 
intracranial involvement; Group A was made up of 32 
patients whose tumors invading the cranial fossa, Group B 
consisted of 46 patients whose tumors invading the 
intracranial region or cerebra. Acute and late morbidities 
were evaluated by the RTOG, the RTOG/ EORTC and the 
CTCAE (version 4.0). 
 
Results: The 5-year local control and overall survival rates of 
all patients were 65 % and 60 %, respectively. Median survival 
time was 74.4 months. In total 45 patients died, the major 
cause of death was distant metastases (67%). The 5-year local 
control rates were 71% for Group A and 56% for Group B. The 
5-year overall survival rates were 74% for Group A and 49% 
for Group B. In univariate analysis using log-rank test, there 
were no significant differences in local control and overall 
survival rates between the two groups. There was no 
evidence of any unexpected severe acute (grade ≥4) and late 
(grade ≥3) reactions to the skin, the mucosa and other 
critical organs. In regard to brain toxicity, 5 of 32 patients 
(16%) in Group A and 9 of 42 patients (21%) in Group B 
developed grade 2 late reactions, which necessitated steroid 
administration temporarily. Four patients in Group B who had 
marginal recurrence received re-irradiation. Therefore, it 
was difficult to evaluate brain toxicity for these patients. 
 
Conclusion: Our results showed acceptable brain toxicities 
and excellent therapeutic effectiveness for unresectable 
adenoid cystic carcinomas invading the skull base. 
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Purpose or Objective: Proton beam therapy (PT) has 
experienced increasing interest over time especially in 
pediatric malignancies as PT offers a chance to reduce post-
treatment late effects. The West German Proton Therapy 
Center Essen (WPE) started treatments for pediatric tumors 
in June 2013. Since September 2013 all children under the 
age of 18 years were enrolled in the standardized prospective 
